​

Emergent BioSolutions (EBS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EBS Stock Forecast

Emergent BioSolutions (EBS) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $51.50, with a high of $65.00 and a low of $38.00. This represents a 1014.72% increase from the last price of $4.62.

- $13 $26 $39 $52 $65 High: $65 Avg: $51.5 Low: $38 Last Closed Price: $4.62

EBS Stock Rating

Emergent BioSolutions stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 2 Hold (14.29%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 2 11 Strong Sell Sell Hold Buy Strong Buy

EBS Price Target Upside V Benchmarks

TypeNameUpside
StockEmergent BioSolutions1014.72%
SectorHealthcare Stocks 35.94%
IndustrySpecialty & Generic Drug Manufacturers Stocks45.40%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.62$4.62$4.62
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2511--13
Mar, 2511--13
Feb, 2511--13
Jan, 2511--13
Dec, 2411--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 04, 2022Wells Fargo$38.00$33.0614.94%722.51%
Apr 29, 2022Chardan Capital$65.00$33.9891.29%1306.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 30, 2024H.C. WainwrightBuyinitialise
Aug 22, 2024Rodman & RenshawBuyinitialise
Aug 16, 2024Benchmark Co.UnderperformUnderperformhold
Jun 24, 2024Benchmark Co.UnderperformUnderperformhold
Jun 20, 2024BenchmarkBuyBuyhold
Mar 07, 2024BenchmarkPositiveBuyupgrade
Apr 10, 2023BenchmarkHoldPositiveupgrade
Nov 10, 2022BenchmarkHolddowngrade
Apr 29, 2022Chardan CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.79$4.10$-4.47$-14.85$-3.60----
Avg Forecast$7.35$5.89$-1.90$-4.84$-1.64$1.29$1.27$1.11$1.31
High Forecast$7.37$5.91$-1.89$-4.63$-1.57$1.34$1.33$1.16$1.37
Low Forecast$7.32$5.86$-1.91$-5.05$-1.71$1.23$1.22$1.06$1.25
Surprise %-21.22%-30.39%135.26%206.82%119.51%----

Revenue Forecast

$1B $1B $1B $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.56B$1.79B$1.12B$1.05B$1.04B----
Avg Forecast$1.55B$1.74B$1.09B$1.07B$1.10B$1.11B$1.05B$1.16B$1.22B
High Forecast$1.55B$1.74B$1.09B$1.10B$1.12B$1.15B$1.07B$1.20B$1.26B
Low Forecast$1.54B$1.73B$1.08B$1.03B$1.09B$1.07B$1.03B$1.13B$1.18B
Surprise %0.63%3.12%3.09%-1.65%-4.99%----

Net Income Forecast

$-2B $-2B $-1B $-500M $0 $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$305.80M$219.50M$-223.80M$-760.50M$-190.60M----
Avg Forecast$267.72M$166.73M$-102.72M$-760.50M$-83.80M$65.79M$65.05M$56.83M$67.07M
High Forecast$326.26M$225.71M$-3.37M$115.75M$-80.16M$68.65M$67.88M$59.30M$69.98M
Low Forecast$209.18M$107.76M$-202.07M$-1.64B$-87.44M$62.94M$62.23M$54.36M$64.16M
Surprise %14.22%31.65%117.87%-127.45%----

EBS Forecast FAQ

Is Emergent BioSolutions stock a buy?

Emergent BioSolutions stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Emergent BioSolutions is a favorable investment for most analysts.

What is Emergent BioSolutions's price target?

Emergent BioSolutions's price target, set by 14 Wall Street analysts, averages $51.5 over the next 12 months. The price target range spans from $38 at the low end to $65 at the high end, suggesting a potential 1014.72% change from the previous closing price of $4.62.

How does Emergent BioSolutions stock forecast compare to its benchmarks?

Emergent BioSolutions's stock forecast shows a 1014.72% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the specialty & generic drug manufacturers stocks industry (45.40%).

What is the breakdown of analyst ratings for Emergent BioSolutions over the past three months?

  • April 2025: 33.33% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 33.33% Strong Sell.
  • March 2025: 33.33% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 33.33% Strong Sell.
  • February 2025: 33.33% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 33.33% Strong Sell.

What is Emergent BioSolutions’s EPS forecast?

Emergent BioSolutions's average annual EPS forecast for its fiscal year ending in December 2025 is $1.29, marking a -135.83% decrease from the reported $-3.6 in 2024. Estimates for the following years are $1.27 in 2026, $1.11 in 2027, and $1.31 in 2028.

What is Emergent BioSolutions’s revenue forecast?

Emergent BioSolutions's average annual revenue forecast for its fiscal year ending in December 2025 is $1.11B, reflecting a 6.39% increase from the reported $1.04B in 2024. The forecast for 2026 is $1.05B, followed by $1.16B for 2027, and $1.22B for 2028.

What is Emergent BioSolutions’s net income forecast?

Emergent BioSolutions's net income forecast for the fiscal year ending in December 2025 stands at $65.79M, representing a -134.52% decrease from the reported $-191M in 2024. Projections indicate $65.05M in 2026, $56.83M in 2027, and $67.07M in 2028.